참고문헌
- Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30. https://doi.org/10.1186/1750-1172-5-30
- Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009;119:2561-7. https://doi.org/10.1161/CIRCULATIONAHA.108.841494
- Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-8. https://doi.org/10.1111/j.0022-202X.2004.22425.x
- Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-46. https://doi.org/10.1046/j.1523-1755.2002.00675.x
- Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008;105:2812-7. https://doi.org/10.1073/pnas.0712309105
- Wijburg FA, Benichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, et al. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One 2015;10:e0124987. https://doi.org/10.1371/journal.pone.0124987
- Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010;25:2168-77. https://doi.org/10.1093/ndt/gfp528
- Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64: 801-7. https://doi.org/10.1046/j.1523-1755.2003.00160.x
- Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY, et al. miR-21 overexpression enhances TGFbeta1- induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014;392: 163-72. https://doi.org/10.1016/j.mce.2014.05.018
- Jeon YJ, Jung N, Park JW, Park HY, Jung SC. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide. PLoS One 2015;10:e0136442. https://doi.org/10.1371/journal.pone.0136442
- Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 2015;21:998-1009. https://doi.org/10.1038/nm.3902
- Morizane R, Fujii S, Monkawa T, Hiratsuka K, Yamaguchi S, Homma K, et al. miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep 2014;4:4578.
- Liu T, Nie F, Yang X, Wang X, Yuan Y, Lv Z, et al. MicroRNA-590 is an EMT-suppressive microRNA involved in the TGFbeta signaling pathway. Mol Med Rep 2015;12:7403-11. https://doi.org/10.3892/mmr.2015.4374
- Morizane R, Fujii S, Monkawa T, Hiratsuka K, Yamaguchi S, Homma K, et al. miR-363 induces transdifferentiation of human kidney tubular cells to mesenchymal phenotype. Clin Exp Nephrol 2015.
- Xiao L, Zhou X, Liu F, Hu C, Zhu X, Luo Y, et al. MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis. Lab Invest 2015;95:817-32. https://doi.org/10.1038/labinvest.2015.57
- Huang Y, Tong J, He F, Yu X, Fan L, Hu J, et al. miR-141 regulates TGF-beta1-induced epithelialmesenchymal transition through repression of HIPK2 expression in renal tubular epithelial cells. Int J Mol Med 2015;35:311-8. https://doi.org/10.3892/ijmm.2014.2008
- Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015;87:3-14. https://doi.org/10.1016/j.addr.2015.05.001
- Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis 2015;35:3-11. https://doi.org/10.1055/s-0034-1397344
- Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 2010;116:117-25. https://doi.org/10.1016/j.ygyno.2009.08.009
- Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011;22:1686-98. https://doi.org/10.1091/mbc.E11-02-0103
- Oba S, Mizutani T, Suzuki E, Nishimatsu H, Takahashi M, Ogawa Y, et al. A useful method of identifying of miRNAs which can down-regulate Zeb-2. BMC Res Notes 2013;6:470. https://doi.org/10.1186/1756-0500-6-470
- Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013;132:745-54. https://doi.org/10.1002/ijc.27708
- Zhang L, Sun J, Wang B, Ren JC, Su W, Zhang T. MicroRNA-10b Triggers the Epithelial-Mesenchymal Transition (EMT) of Laryngeal Carcinoma Hep-2 Cells by Directly Targeting the E-cadherin. Appl Biochem Biotechnol 2015;176:33-44. https://doi.org/10.1007/s12010-015-1505-6
- Palmieri D, Capponi S, Geroldi A, Mura M, Mandich P, Palombo D. TNFalpha induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated down-regulation of miR-149. Biochem Biophys Res Commun 2014;443:246-51. https://doi.org/10.1016/j.bbrc.2013.11.092
- Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem 2015;35:499-515. https://doi.org/10.1159/000369715
- Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013;108:644-52. https://doi.org/10.1038/bjc.2013.8
- Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013;91:431-7. https://doi.org/10.1007/s00109-013-1020-6
- Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol 2013;4:21.
- Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013;15:281-95. https://doi.org/10.1593/neo.122010
- Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG, Sun BM. MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol 2012;25:871-81. https://doi.org/10.1177/039463201202500405
- Zhang Y, Guo X, Xiong L, Yu L, Li Z, Guo Q, et al. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway. Mol Cancer 2014;13:253. https://doi.org/10.1186/1476-4598-13-253
- Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, et al. MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene 2014;33:4496-507. https://doi.org/10.1038/onc.2014.10
- Li P, Shan JX, Chen XH, Zhang D, Su LP, Huang XY, et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res 2015;25:588-603. https://doi.org/10.1038/cr.2015.51
- Shin YJ, Jeon YJ, Jung N, Park JW, Park HY, Jung SC. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease. Mol Med Rep 2015;12:5049-57. https://doi.org/10.3892/mmr.2015.4010
- Ke Y, Zhao W, Xiong J, Cao R. miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochem Res Int. 2013;2013:506731.
- Zuo JH, Zhu W, Li MY, Li XH, Yi H, Zeng GQ, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011;112: 2508-17. https://doi.org/10.1002/jcb.23175
- Shiozuka C, Taguchi A, Matsuda J, Noguchi Y, Kunieda T, Uchio-Yamada K, et al. Increased globotriaosylceramide levels in a transgenic mouse expressing human a1,4-galactosyltransferase and a mouse model for treating Fabry disease. J Biochem 2011;149:161-70. https://doi.org/10.1093/jb/mvq125